Tissue harvest still defines reconstructive surgery.
It shouldn't.
Each year in the United States, more than 50,000 patients undergo a graft-harvesting surgery to obtain tissue used in urethral, bladder, tracheal, or esophageal reconstruction. WeaveBio is changing that — with one synthetic platform designed from the ground up to integrate, regenerate, and resorb.
Bilayer Silk Fibroin (BLSF) — engineered to regenerate, not replace.
BLSF is a fully synthetic, animal-free bilayer scaffold built from two engineered films of silk fibroin: an impermeable outer film that acts as a fluid barrier and guides epithelialization, and a porous inner film that supports cell ingrowth, tissue infiltration, and vascularization.
Unlike autografts and xenografts, BLSF is tunable — porosity, tensile strength, elongation, and degradation window can each be engineered to match the regenerative biology of the target organ. This is what allows a single platform to serve indications as different as urethra, bladder, and trachea.
Off-the-shelf. Sterilizable. Animal-free. One device, one manufacturing process, economies of scale across multiple indications.
Built by an experienced operating team
and a deep advisory bench.
Leadership & Advisory Board — WeaveBio Therapeutics, May 2026